Renal cell carcinoma (RCC), the most frequent type of kidney cancer, responsible for 5% of oncological diagnosis in men and for 3% in women, representing the sixth most frequent cancer worldwide, is a constant challenge for uro-oncologists.
Acute myeloid leukemia (AML) is a myeloproliferative neoplasia, characterized by clonal evolution and genetic heterogeneity.